Voyager Therapeutics, Inc. $VYGR Shares Acquired by American Century Companies Inc.

American Century Companies Inc. increased its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 7.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 131,521 shares of the company’s stock after acquiring an additional 8,795 shares during the period. American Century Companies Inc.’s holdings in Voyager Therapeutics were worth $445,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics in the 4th quarter valued at about $29,000. Tower Research Capital LLC TRC lifted its stake in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares during the last quarter. CWM LLC lifted its stake in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after purchasing an additional 9,376 shares during the last quarter. Privium Fund Management B.V. acquired a new stake in Voyager Therapeutics during the first quarter valued at approximately $73,000. Finally, Tema Etfs LLC acquired a new stake in Voyager Therapeutics during the fourth quarter valued at approximately $85,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wedbush cut their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $13.25.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $4.24 on Friday. The company has a market cap of $235.19 million, a PE ratio of -2.29 and a beta of 0.90. Voyager Therapeutics, Inc. has a 52 week low of $2.64 and a 52 week high of $8.27. The firm has a 50 day simple moving average of $3.37 and a 200 day simple moving average of $3.42.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. On average, equities analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.